Cancer Family
Transitional Cell Neoplasm
CI-CAN-00000374Explore in graph →
Non-malignant254 active trials5 approved drugs23 evidence items
- NCIt
- C6783
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000374Explore in graph →
Clinical trials
753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | completed | — | 275 | Gynecologic Oncology GroupNETWORK | 1 | Oct 28, 2016 | clinicaltrials |
| NCT00683059 | Single Agent Abraxane as Second Line Therapy in Bladder Cancer | completed | Phase 2 | 48 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors |
| completed |
| Phase 1 |
| 18 |
| Roswell Park Cancer InstituteOTHER |
| 1 |
| Oct 4, 2016 |
| clinicaltrials |
| NCT00362713 | Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection | completed | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT02471547 | Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT | unknown | N/A | 300 | Sheba Medical CenterOTHER_GOV | 1 | Apr 28, 2016 | clinicaltrials |
| NCT01606345 | Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma | completed | Phase 1 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT00588666 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT00612326 | Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging | completed | — | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2015 | clinicaltrials |
| NCT01599013 | JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin(JASINT1) | completed | Phase 2 | 69 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT00059787 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00633789 | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | completed | Phase 2 | 597 | Bristol-Myers SquibbINDUSTRY | 9 | Oct 9, 2015 | clinicaltrials |
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | Hoosier Cancer Research NetworkOTHER | 0 | Aug 19, 2015 | clinicaltrials |
| NCT01103544 | JAVLOR® Online Non-Interventional Trial(JONAS-1) | completed | — | 200 | Pierre Fabre Pharma GmbHINDUSTRY | 1 | May 13, 2015 | clinicaltrials |
| NCT01600339 | A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) | completed | Phase 2 | 19 | Rambam Health Care CampusOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT02278978 | BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma | unknown | Phase 2 | 129 | National Taiwan University HospitalOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00060359 | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 32 | Gynecologic Oncology GroupNETWORK | 1 | May 8, 2015 | clinicaltrials |
| NCT00814086 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 23 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Dec 31, 2014 | clinicaltrials |
| NCT02326909 | Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma | completed | N/A | 26 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 30, 2014 | clinicaltrials |
| NCT01294293 | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 1 | 20 | Gynecologic Oncology GroupNETWORK | 1 | Dec 25, 2014 | clinicaltrials |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01487915 | Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma(COACH) | unknown | Phase 2 | 80 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01490437 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma(PECULIAR) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 0 | Apr 29, 2014 | clinicaltrials |
| NCT01395225 | Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer | completed | — | 32 | University of British ColumbiaOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT01304173 | Retrospective Chart Review of Valstar | completed | — | 113 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01993966 | EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells | unknown | — | 25 | National Taiwan University HospitalOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01968928 | The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma | unknown | — | 25 | National Taiwan University HospitalOTHER | 1 | Oct 28, 2013 | clinicaltrials |
| NCT00002913 | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT01215877 | Tesetaxel for Previously Treated Patients With Bladder Cancer | unknown | Phase 2 | 33 | Genta IncorporatedINDUSTRY | 2 | Jul 11, 2012 | clinicaltrials |
| NCT00867633 | Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan | unknown | — | 100 | National Taiwan University HospitalOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00696007 | Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer | withdrawn | Phase 2 | 0 | Lahey ClinicOTHER | 1 | Feb 17, 2012 | clinicaltrials |
| NCT00714025 | A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy | completed | Phase 2 | 40 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jan 24, 2012 | clinicaltrials |
| NCT01378052 | DNA Methylation and Urothelial Carcinoma | unknown | — | 200 | China Medical University HospitalOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT01360723 | DNA Methylation and Arsenic-associated Urothelial Carcinoma | unknown | — | 600 | China Medical University HospitalOTHER | 1 | May 27, 2011 | clinicaltrials |
| NCT01189838 | The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma | unknown | — | 100 | Far Eastern Memorial HospitalOTHER | 1 | Oct 7, 2010 | clinicaltrials |
| NCT00101608 | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 15 | Mar 2, 2010 | clinicaltrials |
| NCT00315237 | Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract | completed | Phase 3 | 364 | Pierre Fabre MedicamentINDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00077688 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 44 | Achieve Life SciencesINDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00854464 | Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma | unknown | — | 420 | National Taiwan University HospitalOTHER | 1 | Mar 3, 2009 | clinicaltrials |
| NCT00216801 | Relationship of Ochratoxin A to Upper Urologic Cancers | completed | — | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jan 21, 2009 | clinicaltrials |
| NCT00109655 | Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure | unknown | Phase 1 | 75 | Cell GenesysINDUSTRY | 2 | Oct 3, 2008 | clinicaltrials |
| NCT00172367 | Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma | withdrawn | Phase 2 | 80 | National Taiwan University HospitalOTHER | 1 | Sep 26, 2008 | clinicaltrials |
| NCT00001381 | A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00191971 | 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen | completed | Phase 2 | 40 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 6, 2007 | clinicaltrials |
| NCT00154687 | Weekly TP-HDFL in the Treatment of Advanced TCC | completed | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Jul 31, 2007 | clinicaltrials |
| NCT00173862 | Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC | completed | Phase 2 | 18 | National Taiwan University HospitalOTHER | 1 | Jul 25, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Oct 28, 2016source: clinicaltrials